Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 3/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 6/20 | 0.33 |
| ▸ | EDNRA | P25101 | 2/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4914641 | 0.90 | MAPT (0.36) | PTGESPKMPOLBTP53 | |
| SCHEMBL4924856 | 0.84 | PTGES (0.39) | PTGESPKMPTGDRPPARGEDNRA | |
| SCHEMBL4922669 | 0.81 | PTGDR (0.44) | PTGESPKMPTGDRPPARGEDNRA | |
| SCHEMBL4918295 | 0.79 | PTGDR (0.42) | PTGESPKMPTGDREDNRAPTGDR2 | |
| SCHEMBL4916723 | 0.79 | PTGES (0.37) | PTGESPKMPTGDREDNRAPTGDR2 | |
| SCHEMBL4913287 | 0.78 | PTGES (0.39) | PTGESPKMPPARGEDNRA | |
| SCHEMBL4924283 | 0.74 | PTGDR (0.44) | PTGESPKMPTGDRPPARGEDNRA | |
| SCHEMBL4916843 | 0.73 | MAPT (0.47) | PTGESPTGDREDNRA | |
| SCHEMBL4926075 | 0.72 | PTGES (0.54) | PTGESPPARGPPARA | |
| SCHEMBL4922258 | 0.72 | MAPT (0.47) | PTGESPTGDREDNRATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080249091-A1 | Indoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2008-10-09 | — | — | US | disclosed |
| EP-1844013-A1 | INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION | Biolipox AB (SE) | 2007-10-17 | — | — | EP | disclosed |
| WO-2006077364-A1 | INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249091-A1 | Indoles Useful in the Treatment of Inflammation | IDO1, IDO2, ARG1 | PTGES 35/4885PKM 2717/4885PTGDR 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.